BJP leaders go into huddle ahead of counting of votes

Panaji (Goa)/Bhopal (Madhya Pradesh), Bengaluru(Karnataka)/New Delhi [India], June 8 (ANI): With the government allowing the re-opening of restaurants and eateries from Monday, these establishments re-opened across several states on Monday including in Goa, Madhya Pradesh and Delhi, with necessary precautions in place amid COVID-19 crisis.

Restaurants reopened in Panaji today after relaxations in lockdown.

Speaking to ANI, Goa Hotel and Restaurant Association President, Gaurish Dhond said, "We expect that not more than 25 per cent of restaurants will reopen because our labour force is dependent upon migrant workers who have gone to their homes".

"Every guest will be checked with a thermal gun, we will provide them with a sanitizer and a digital menu most probably. We would like to request our customers to pay online. Residential hotels are also allowed to operate and guidelines have been issued for them," he added.

Bars are not allowed to operate, he added.

While religious places across the country were thrown open today, worship places continued to remain closed in Goa till June 30.

In Bhopal restaurants opened but with fewer customers venturing to eat outside.

Speaking to ANI, C Kumaran, Manager, India Coffee House, New Market said, "We will conduct a temperature check for customers at the entry point. Then the customers will have to wash and sanitize their hands only then they will be allowed to sit inside. Only two persons will be allowed to sit on a four-seat table."

"This restaurant has a seating capacity of around 120 persons which has now been reduced to 50. Even in the kitchen, staff capacity has been reduced to 50 per cent," he added.

Meanwhile, malls re-opened in Bengaluru today, people along with staff members were allowed to enter inside Garuda Mall while maintaining social distancing.

"As per government norms, we are following all the preventive measures. Staff and other people are being sanitized and then only allowed inside the mall. The mall has been deep cleaned. People entering the mall should have Aarogya Setu App installed in their mobile phones if not, they will be sent back," said John Joseph, Manager, Garuda Mall.

Restaurants re-opened in the national capital as Delhi CM Arvind Kejriwal announced yesterday that all restaurants and malls are allowed to resume operations from today.

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.